KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Non-Current Assets (2016 - 2025)

Nektar Therapeutics has reported Non-Current Assets over the past 16 years, most recently at $14.1 million for Q4 2025.

  • Quarterly results put Non-Current Assets at $14.1 million for Q4 2025, down 66.77% from a year ago — trailing twelve months through Dec 2025 was $81.4 million (down 56.77% YoY), and the annual figure for FY2025 was $14.1 million, down 66.77%.
  • Non-Current Assets for Q4 2025 was $14.1 million at Nektar Therapeutics, down from $20.0 million in the prior quarter.
  • Over the last five years, Non-Current Assets for NKTR hit a ceiling of $357.5 million in Q1 2021 and a floor of $14.1 million in Q4 2025.
  • Median Non-Current Assets over the past 5 years was $69.0 million (2023), compared with a mean of $131.1 million.
  • Biggest five-year swings in Non-Current Assets: crashed 76.19% in 2023 and later rose 7.78% in 2024.
  • Nektar Therapeutics' Non-Current Assets stood at $321.6 million in 2021, then plummeted by 48.81% to $164.6 million in 2022, then tumbled by 59.1% to $67.3 million in 2023, then crashed by 36.79% to $42.6 million in 2024, then crashed by 66.77% to $14.1 million in 2025.
  • The last three reported values for Non-Current Assets were $14.1 million (Q4 2025), $20.0 million (Q3 2025), and $21.0 million (Q2 2025) per Business Quant data.